Nektar Therapeutics announced that on January 21, 2026, its Board of Directors granted non-qualified stock options to purchase 1,600 shares of common stock to a newly-hired employee under the company’s 2025 Inducement Plan. The options have an exercise price of $36.92 per share, matching the closing price on the grant date. The options have an eight-year term and will vest over four years, with one quarter vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, contingent on continued employment with the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF74932) on January 30, 2026, and is solely responsible for the information contained therein.